Trial
NCT00985946
Study of Panobinostat in Patients With Neuroendocrine Tumors
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
University of Wisconsin, Madison
Collaborators
Novartis Pharmaceuticals
Condition
Neuroendocrine Tumors
Intervention
panobinostat (LBH589)
Why stopped
Study did not meet statistical requirements to continue.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-12-09